Amarin Corp Plc (AMRN)

[KCSVEN]

2q 2020 for direct to consumer not great....is what it is but puts a limit on 2020 earnings, at least extra reps will be fully trained after expanded label and ready for full 2020 sales effort.
The note:
“Vascepa will generate billions of dollars in revenue in the years to come, the history of other therapies for chronic conditions suggests that growth builds over multiple years”

Is typical JT conservatism but also realistic, they will take years to get inventory up, sales up, GIA is a long term play with all the long term risks and rewards.

They should do a billion in revenue in 2020, how much more than that not clear, but that knocks another year off before generics. Maybe EVAPORATE trial results gives a big boost that will help bridge the gap to direct to consumer advertising, Amarin has not really mentioned these results coming in recent presentations or press releases at all.

Cash balance growing is nice, see what happens with all the new hires. Revenue was above estimates, raised guidance is nice, wish low end was set at 400 million.